Nourish has secured US$100m funding to scale its nutrition-first care platform for chronic disease and metabolic health.
The Series C round brings the company’s total funding to US$215m and values it at US$1.75bn.
Nourish combines registered dietitians with AI-powered care agents to tackle chronic disease and improve long-term outcomes.
Co-founder Aidan Dewar said: “Chronic disease is the biggest cost burden in U.S. healthcare, yet patients still receive fragmented, reactive care.
“We’ve built a care model and technology platform focused on lasting lifestyle change, better outcomes, lower costs, and a stronger patient experience.
“This funding will help us meet growing demand at scale.”
Founded in 2021 in New York by Dewar, Sam Perkins and Stephanie Liu, Nourish says it has become the largest dietitian-led metabolic health clinic in the US.
The company says it works with more than 10,000 dietitians and serves patients across all 50 US states through major health plan partnerships.
It focuses on reversing chronic disease through a virtual care model that pairs human specialists with intelligent software designed to support behaviour change, care co-ordination and long-term patient engagement.
Its platform connects every patient with a registered dietitian while integrating lab testing, medication management, GLP-1 prescribing and virtual medical support.
GLP-1 medicines are drugs that mimic a gut hormone involved in appetite and blood sugar control. They are used in some patients for diabetes and weight management.
Patients also interact with a digital health agent through Nourish’s mobile app, which tracks progress and co-ordinates care.
On the provider side, the company says AI copilots reduce administrative work and surface patient insights in real time.
Nourish enters a competitive metabolic health market accelerated by the GLP-1 boom.
Companies including Omada Health, Noom, Calibrate and Found are also racing to combine obesity treatment with virtual care.
Nourish says its approach is differentiated by a nutrition-first model and its network of more than 10,000 dietitians.
The Series C round was led by Menlo Ventures, with backing from Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak and Operator Partners.
J.P. Sanday, partner at Menlo Ventures, said: “Nearly 200 million Americans are affected by chronic disease, yet outcomes remain poor despite trillions spent.
“In just four years, Nourish has built an impressive model with 10,000 dietitians, strong payer partnerships, and measurable clinical results.
“Few companies achieve all of that.”
The new funding will be used to expand Nourish’s clinical network, strengthen insurer and employer partnerships and deepen its technology platform.
